Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Reardon, D A, Dresemann, G, Taillibert, S, Campone, M, van den Bent, M, Clement, P, Blomquist, E, Gordower, L, Schultz, H, Raizer, J, Hau, P, Easaw, J, Gil, M, Tonn, J, Gijtenbeek, A, Schlegel, U, Bergstrom, P, Green, S, Weir, A, Nikolova, Z
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795431/
https://www.ncbi.nlm.nih.gov/pubmed/19904263
http://dx.doi.org/10.1038/sj.bjc.6605411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795431/
https://www.ncbi.nlm.nih.gov/pubmed/19904263
http://dx.doi.org/10.1038/sj.bjc.6605411

Ejemplares similares